This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ISIS 104838

Ionis Pharmaceuticals, Inc.

Drug Names(s): ISIS 104838

Deal Structure: For the joint venture, OraSense Ltd, lan and ISIS both provided technology and funding and will receive royalties on milestone payments and royalties fordevelopment products. lan purchased 910,844 shares of ISIS common for $15 million, 120,150 shares of ISISSeries A convertible preferred (convertible into ISIS common after March 31, 2002 at 125% of 60-day tradingaverage or into 30.1% share of OraSense). lan received a five year option for 215,000 shares of ISIS commonat $24/share. lan committed to purchase ISIS convertible debt in an amount equal to Isiss share ofOraSenses funding until March 31, 2002.

Perrigo and Elan
In December 2013, Perrigo and Elan announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement at approximately US$8.6 billion. In connection with the acquisition, Perrigo and Elan have been combined under a new company incorporated in Ireland and have adopted the global name Perrigo...See full deal structure in Biomedtracker

Partners: Perrigo Company PLC

ISIS 104838 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug